Baseline characteristics of patients by inappropriate shocks
| Characteristics | Overall population (N=1698) | Patients receiving ≥1 inappropriate shock (N=281) | Patients without inappropriate shock (N=1417) | p Value* |
|---|---|---|---|---|
| Demographic | ||||
| Male, N (%) | 1389 (81.8) | 220 (78.3) | 1169 (82.5) | 0.095 |
| Age (years), mean±SD | 61.5±13.5 | 57.5±15.1 | 62.3±13.0 | ≤0.001 |
| Cardiac condition, N (%) | ||||
| Non-structural heart disease | 110 (6.5) | 23 (8.2) | 87 (6.1) | 0.002 |
| Ischaemic cardiomyopathy | 988 (58.2) | 137 (48.8) | 851 (60.1) | |
| Non-ischaemic cardiomyopathy | 600 (35.3) | 121 (43.1) | 479 (33.8) | |
| ICD indication, N (%) | ||||
| Primary prevention | 863 (50.8) | 112 (39.9) | 751 (53.0) | ≤0.001 |
| Secondary prevention | 835 (49.2) | 169 (60.1) | 666 (47.0) | |
| Clinical parameters, N (%) | ||||
| Hypertension | 634 (37.3) | 96 (34.2) | 538 (38.0) | 0.228 |
| Diabetes | 367 (21.6) | 45 (16.0) | 322 (22.7) | 0.013 |
| Atrial flutter/fibrillation | 419 (24.7) | 85 (30.2) | 334 (23.6) | 0.018 |
| Renal failure | 315 (18.6) | 42 (14.9) | 273 (19.3) | 0.089 |
| Prior revascularisation | 733 (43.2) | 91 (32.4) | 642 (45.3) | ≤0.001 |
| NYHA class 3–4 | 289 (17.0) | 22 (7.8) | 267 (18.8) | ≤0.001 |
| LVEF (%), mean±SD | 34.7±14.8 | 39.3±15.5 | 33.8±14.4 | 0.002 |
| Drugs, N (%) | ||||
| β Blocker | 1252 (73.7) | 178 (63.3) | 1074 (75.8) | ≤0.001 |
| Class I antiarrhythmic | 47 (2.8) | 10 (3.6) | 37 (2.6) | 0.376 |
| Class III antiarrhythmic | 601 (35.4) | 114 (40.6) | 487 (34.4) | 0.047 |
| ICD type, N (%) | ||||
| Single chamber | 354 (20.8) | 67 (23.8) | 287 (20.3) | 0.009 |
| Dual chamber | 1067 (62.8) | 185 (65.8) | 882 (62.2) | |
| CRT-D | 277 (16.3) | 29 (10.3) | 248 (17.5) | |
*For comparison between patients with and without inappropriate shock(s).
CRT-D, cardiac resynchronisation (with or without an atrial lead); ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.